IART — Integra LifeSciences Holdings Income Statement
0.000.00%
Last trade - 00:00
- $2.27bn
- $3.46bn
- $1.54bn
- 71
- 65
- 23
- 52
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,518 | 1,372 | 1,542 | 1,558 | 1,542 |
Cost of Revenue | |||||
Gross Profit | 978 | 886 | 977 | 982 | 973 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,426 | 1,242 | 1,309 | 1,322 | 1,431 |
Operating Profit | 91.3 | 130 | 233 | 235 | 111 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 60.1 | 93.5 | 215 | 214 | 81.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 50.2 | 134 | 169 | 181 | 67.7 |
Net Income Before Extraordinary Items | |||||
Net Income | 50.2 | 134 | 169 | 181 | 67.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 50.2 | 134 | 169 | 181 | 67.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.33 | 2.25 | 2.39 | 2.75 | 2.52 |